1. Home
  2. MKTW vs SCLX Comparison

MKTW vs SCLX Comparison

Compare MKTW & SCLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MarketWise Inc.

MKTW

MarketWise Inc.

N/A

Current Price

$18.50

Market Cap

54.6M

Sector

Technology

ML Signal

N/A

Logo Scilex Holding Company

SCLX

Scilex Holding Company

HOLD

Current Price

$5.41

Market Cap

55.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MKTW
SCLX
Founded
1999
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
54.6M
55.1M
IPO Year
2020
2020

Fundamental Metrics

Financial Performance
Metric
MKTW
SCLX
Price
$18.50
$5.41
Analyst Decision
Hold
Analyst Count
1
0
Target Price
$20.00
N/A
AVG Volume (30 Days)
15.9K
37.5K
Earning Date
05-07-2026
04-10-2026
Dividend Yield
10.20%
N/A
EPS Growth
1183.33
N/A
EPS
N/A
N/A
Revenue
$512,403,000.00
$30,253,000.00
Revenue This Year
$1.52
$122.52
Revenue Next Year
$4.55
$186.30
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$13.49
$4.20
52 Week High
$22.83
$34.27

Technical Indicators

Market Signals
Indicator
MKTW
SCLX
Relative Strength Index (RSI) 49.12 33.73
Support Level $16.22 $4.20
Resistance Level $21.40 $7.77
Average True Range (ATR) 0.56 0.30
MACD 0.05 0.03
Stochastic Oscillator 74.16 16.67

Price Performance

Historical Comparison
MKTW
SCLX

About MKTW MarketWise Inc.

Marketwise Inc is a multi-brand subscription services platform providing premium financial research, software, education, and tools for investors. Its products are built for high-value financial research, education, actionable investment ideas, and investment software. It is a digital, direct-to-consumer company offering its research across a variety of platforms, including mobile, desktop, and tablets.

About SCLX Scilex Holding Company

Scilex Holding Co is focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. It targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. Its commercial products are: ZTlidoO for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a potential first-line treatment ready-to-use oral solution for the acute treatment of migraine in adults and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.

Share on Social Networks: